The median starting dose from the two trials by Achilles was 15M cells, but with some changes to the ex vivo expansion, the highest dose level tested ...
The PhII is ongoing, with data for both endpoints expected this year. Also, a new paper. From it: ''Intranasal NEO100 was well tolerated at all ...
The IDSMC (Independent Data and Safety Monitoring Committee) has completed its first review of the ongoing, PhI/II CHIRON (advanced NSCLC) and THETIS ...
@daniel Thanks. Hopefully, there will be some more case reports, or a series published in the (near) future. As for development, I hope they have th...
In this paper, it was shown that inhibition of autophagy enhanced sensitivity to dual immune checkpoint inhibition (anti-CTLA-4 plus anti-PD-1)/p> ...
PACT Pharma expects clinical data from ten patients this quarter, plus additional as the year goes on (around six per quarter). The goal is to elucida...
Daiichi Sankyo has submitted an IND/span> Also, Replimune has dosed the first patient with RP3/p>
An oral form of devimistat (RFL-618) is in development, as are three second generation compounds (RFL-5800/5990/6520). INDs are expected to be filed e...
A new preclinical study in pancreatic combining it with gemcitabine/p>
An RP2 update. The three responses are now two PRs and one CR, but denominator is nine patients (not six), for a 33% (not 50% originally) ORR.
John, I'm sorry to hear of the loss of your wife. My deepest sympathies to you (and family).
The overall response rate (patients with cutaneous squamous cell carcinoma with at least eight weeks of follow-up) for RP1 plus cemiplimab has increas...
Trillium Therapeutics has update results from early-stage dose-escalation studies of top candidates TTI-621 and TTI-622 [1]. TTI-621 (SIRPa-IgG1 fus...
Encouraging data on Gilead's Magrolimab in MDS and AML [1]. Here is a link to the pivotal trial in MDS [2] and another in AML (this is not pivotal, bu...
@jcancom No problem. Speaking of OVs, Replimmune's lead product (RP1) is currently in three registration-directed clinical trials and if all goes to p...
@daniel Thanks. I know a few companies on Amazon (the U.S. site) claim to sell it, but I don't know if they are trustworthy, and even if so it could b...
The drug with gemcitabine and nab-paclitaxel [1], fully enrolled in one pivotal trial [2], and past the midpoint in another (again, pivotal) [3]. ...
Preclinical data (IACS-010759)/span>
One group has published that certain tumour-reactive CD8+ T-cells are CD39/CD103 double positive [1]. These cells have been found in many solid tumour...
New data on IM156/p>